# EDGAR Filing Document

**Accession Number:** 0001131343
**File Stem:** 0001213900-25-090326
**Filing Date:** 2025-9
**Character Count:** 4646
**Document Hash:** 07a71b7347ffb6fdf74ebfb43536e1ad
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-090326.hdr.sgml**: 20250923

**ACCESSION NUMBER**: 0001213900-25-090326

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250923

**FILED AS OF DATE**: 20250923

**DATE AS OF CHANGE**: 20250923

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALTERITY THERAPEUTICS LTD
- **CENTRAL INDEX KEY:** 0001131343
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** C3
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-49843
- **FILM NUMBER:** 251331746

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **PROVINCE COUNTRY:** C3
- **BUSINESS PHONE:** 61 3 9349 4906

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** LEVEL 3, 460 BOURKE STREET
- **CITY:** MELBOURNE
- **PROVINCE COUNTRY:** C3

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRANA BIOTECHNOLOGY LTD
- **DATE OF NAME CHANGE:** 20010105

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-163**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of September 2025**

**Alterity Therapeutics Limited**

(Name of Registrant)

**Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia**

(Address of Principal Executive Office)

**Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.**

Form 20-F ☒ Form 40-F ☐

**This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. [333-251073](http://www.sec.gov/Archives/edgar/data/1131343/000121390020040485/ea130838-s8_alteritytherape.htm), [333-248980](http://www.sec.gov/Archives/edgar/data/1131343/000121390020027969/ea127207-s8_alteritytherap.htm) and [333-228671](http://www.sec.gov/Archives/edgar/data/1131343/000114420418063081/tv508429_s-8.htm)) and our Registration Statements on Form F-3 (Files No. [333-274816](http://www.sec.gov/Archives/edgar/data/1131343/000101376223000033/ea185947-f3_alteritytherape.htm), [333-251647](http://www.sec.gov/Archives/edgar/data/1131343/000121390020044324/ea132148-f3_alteritytherape.htm), [333-231417](http://www.sec.gov/Archives/edgar/data/1131343/000114420419025615/tv521271_f3.htm) and [333-250076](http://www.sec.gov/Archives/edgar/data/1131343/000121390020036934/ea129831-f3_alteritytherap.htm))**

**ALTERITY THERAPEUTICS LIMITED**

**(a development stage enterprise)**

The following exhibits are submitted:

99.1 [Date of AGM and Closing Date for Director Nominations](ea025839501ex99-1_alterity.htm)

**<u>SIGNATURE</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Alterity Therapeutics Limited** | **Alterity Therapeutics Limited** |
| By: | /s/ Geoffrey P. Kempler |
|  | Geoffrey P. Kempler |
|  | Chairman |

---

Date: September 23, 2025

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**23 September 2025**

**ASX Announcement**

**DATE OF AGM AND CLOSING DATE FOR DIRECTOR NOMINATIONS**

Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) (**Alterity** or **the Company**) advises that, in accordance with ASX Listing Rule 3.13.1, its next Annual General Meeting (AGM) will be held at 11.00am (AEDT) on Friday 21 November 2025.

In addition, the closing date for the receipt of nominations from persons wishing to be considered for election as a director is Wednesday 1 October 2025. Any nominations must be received in writing no later than 5.00pm (AEST) on Wednesday 1 October 2025 at the Company's registered office.

Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting, which will be provided to shareholders shortly. The Notice of Meeting will also be available on the ASX Company Announcements Platform and the Company's website at www.alteritytherapeutics.com.

For further information, please contact:

---

| |
|:---|
| /s/ Abby Macnish Niven |
| Abby Macnish Niven |
| CFO & Company Secretary |

---

T: +61 3 9349 4906

E: cfo@alteritytx.com

**Alterity Therapeutics Limited**

**Suite 4, Level 14, 350 Collins Street, Melbourne, VIC 3000 Australia**

**T: +61 (0)3 9349 4906 \| www.alteritytherapeutics.com**